Regulus Therapeutics Inc. (Nasdaq: RGLS) announced interim results from one of the company’s ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV).
Newsroom
Regulus Therapeutics Inc. (Nasdaq: RGLS) announced interim results from one of the company’s ongoing Phase II studies of RG-101 for the treatment of Hepatitis C Virus infection (HCV).